Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | IAPP | P10997 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4772634 | 0.82 | CYP1A2 (0.49) | CYP1A2CYP2C9CYP2C19TDP1NPC1 | |
| SCHEMBL28023546 | 0.81 | POLB (0.49) | CYP1A2CYP2C9CYP2C19TDP1NPC1 | |
| SCHEMBL27873701 | 0.80 | IAPP (0.49) | CYP1A2CYP2C9CYP2C19DRD2DRD3 | |
| SCHEMBL9200148 | 0.79 | TP53 (0.39) | CYP1A2CYP2C9CYP2C19TDP1NPC1 | |
| SCHEMBL934619 | 0.76 | HPGD (0.59) | POLBKMT2AMEN1 | |
| SCHEMBL14473145 | 0.75 | TRPV1 (0.44) | CYP1A2CYP2C9CYP2C19TDP1NPC1 | |
| SCHEMBL330291 | 0.74 | TDP1 (0.56) | TDP1POLBKMT2AMEN1 | |
| SCHEMBL2251512 | 0.74 | POLB (0.45) | CYP1A2CYP2C9CYP2C19TDP1NPC1 | |
| SCHEMBL8847741 | 0.74 | — | — | |
| SCHEMBL8075617 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| EP-1966146-B1 | 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2011-03-02 | — | — | EP | disclosed |
| CN-101341127-A | 4,5-dihydro- (1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | SOLVAY PHARM BV (NL) | 2009-01-07 | — | — | CN | disclosed |
| EP-1966146-A1 | 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS | Solvay Pharmaceuticals B.V. (NL) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071662-A1 | 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142362-A1 | 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | SOLVAY PHARMACEUTICALS B.V. | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142362-A1 | 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | CNR1, CNR2, GPR55 | CYP1A2 337/4885CYP2C9 362/4885CYP2C19 140/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | CYP1A2 2139/4885CYP2C9 2585/4885CYP2C19 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.